Profile of abemaciclib and its potential in the treatment of breast cancer

References

• U.S. Cancer Statistics Working GroupUnited States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based ReportAtlantaU.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute2017 [cited November 28, 2017]. Available from: www.cdc.gov/uscs
   Google Scholar
• National Cancer InstituteSEER Cancer Statistics Factsheets: Breast Cancer [cited November 28, 2017]. Available from: https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• KohlerBAShermanRLHowladerNAnnual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and StateJ Natl Cancer Inst20151076djv04825825511
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkBreast Cancer Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed March 22, 2018
   Google Scholar
• PartridgeAHRumbleRBCareyLAChemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201432293307332925185096
   PubMed Web of Science ®Google Scholar
• SledgeGWNeubergDBernardoPPhase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)J Clin Oncol200321458859212586793
   PubMed Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet2011377976991492321376385
   PubMed Web of Science ®Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol200725233407341417606974
   PubMed Web of Science ®Google Scholar
• KaufmanPAAwadaATwelvesCPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol201533659460125605862
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• KornblumNSZhaoFManolaJRandomized phase II trial of fulbestrant plus everolimus or placebo in post-menopausal women with hormone-receptor positive HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• YardleyDAIsmail-KhanRRMelicharBRandomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitorJ Clin Oncol201331172128213523650416
   PubMed Web of Science ®Google Scholar
• VanarsdaleTBoshoffCArndtKTAbrahamRTMolecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatmentClin Cancer Res201521132905291025941111
   PubMed Web of Science ®Google Scholar
• BarnesDMGillettCECyclin D1 in breast cancerBreast Cancer Res Treat1998521–311510066068
   PubMed Web of Science ®Google Scholar
• LundgrenKBrownMPinedaSEffects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC studyBreast Cancer Res2012142R5722475046
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• StendahlMKronbladARydénLCyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patientsBr J Cancer200490101942194815138475
   PubMed Web of Science ®Google Scholar
• NaiduRWahabNAYadavMMKuttyMKExpression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parametersOncol Rep20029240941611836618
   PubMed Web of Science ®Google Scholar
• DeanJLThangavelCMcclendonAKReedCAKnudsenESTherapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene201029284018403220473330
   PubMed Web of Science ®Google Scholar
• FinnRSAleshinASlamonDJTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersBreast Cancer Res20161811726857361
   PubMed Web of Science ®Google Scholar
• XuHYuSLiuQRecent advances of highly selective CDK4/6 inhibitors in breast cancerJ Hematol Oncol20171019728438180
   PubMed Web of Science ®Google Scholar
• FinnRSMartinMRugoHSPalbociclib and letrozole in advanced breast cancerN Engl J Med2016375201925193627959613
   PubMed Web of Science ®Google Scholar
• CristofanilliMTurnerNCBondarenkoIFulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialLancet Oncol201617442543926947331
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrials.govAccessed November 27, 2017
   Google Scholar
• HortobagyiGNStemmerSMBurrisHARibociclib as first-line therapy for HR-positive, advanced breast cancerN Engl J Med2016375181738174827717303
   PubMed Web of Science ®Google Scholar
• GelbertLMCaiSLinXPreclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineInvest New Drugs201432582583724919854
   PubMed Web of Science ®Google Scholar
• TateSCCaiSAjamieRTSemi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenograftsClin Cancer Res201420143763377424850847
   PubMed Web of Science ®Google Scholar
• FlahertyKTLorussoPMDemicheleAPhase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerClin Cancer Res201218256857622090362
   PubMed Web of Science ®Google Scholar
• InfanteJRCassierPAGerecitanoJFA phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomasClin Cancer Res201622235696570527542767
   PubMed Web of Science ®Google Scholar
• PatnaikARosenLSTolaneySMEfficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumorsCancer Discov20166774075327217383
   PubMed Web of Science ®Google Scholar
• WuTChenZToKKWEffect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivoBiochem Pharmacol2017124294227816545
   PubMed Web of Science ®Google Scholar
• DicklerMNTolaneySMRugoHSMONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancerClin Cancer Res201723175218522428533223
   PubMed Web of Science ®Google Scholar
• SledgeGWToiMNevenPMONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• GoetzMPToiMCamponeMMONARCH 3: abemaciclib as initial therapy for advanced breast cancerJ Clin Oncol201735323638364628968163
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
   PubMed Web of Science ®Google Scholar
• TolaneySMLinNUThorntonDAbemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancerJ Clin Oncol20173515_suppl10191019
   Web of Science ®Google Scholar
• GoelSWangQWattACOvercoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitorsCancer Cell201629325526926977878
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• PatelJMTorousVHackerMRRetinoblastoma (Rb) protein expression in triple-negative breast cancerJ Clin Oncol20173515_suppl10971097
   Web of Science ®Google Scholar
• AsgharUSBarrARCuttsRSingle-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancerClin Cancer Res201723185561557228606920
   PubMed Web of Science ®Google Scholar
• PanHGrayRBraybrookeJ20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 yearsN Engl J Med2017377191836184629117498
   PubMed Web of Science ®Google Scholar
• YoshiokaTHosodaMYamamotoMPrognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancerBreast Cancer201522218519123645542
   PubMed Web of Science ®Google Scholar
• MartinMHurvitzSAChanDFinal results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)Presented at: the 2017 San Antonio Breast Cancer SymposiumDecember 5–9, 2017 Abstract PD5-01
   Google Scholar